Overview of the "Seek and Kill" Escherichia coli (E. coli) System
Experimental Design
Engineering bacterial cells to target and kill pathogens is an alternative to antibiotics that has recently shown promise but has also been stymied by several limitations to the approach. The main limitations have been ineffective diffusion of the secreted "killer" molecule (Saeidi et al., 2011) and lack of sufficient access of "killer" molecules to pathogenic bacteria in biofilms (Flemming & Wingender, 2010) . Biofilms are communities of microorganisms encased in polysaccharides, nucleic acids, and proteins which serve as a barrier to entry for host immune effectors and antimicrobials.
In their study, Hwang et al. designed and tested an engineered bacterial strain (termed "Seek & Kill" E. coli) to overcome these limitations and effectively kill Pseudomonas aeruginosa (PA) cells ( Figure 1) . The "Seek & Kill" E. coli strain contains three engineered modules: 1. Sensing Module. The sensing module uses quorum sensing (the ability of bacteria to communicate and coordinate behavior such as population density through signal molecules) from the target bacteria to turn on the "Seek and Kill" mechanisms. When the quorum sensing molecule (in this case, N-acyl homoserine lactone or AHL secreted by P. aeruginosa) enters the E. coli cell, motility and killing modules are activated. 2. Motility (Chemotaxis) Module. The motility module contains a gene (CheZ) that is expressed after AHL enters the E. coli cell. The result is that the E. coli cells become mobile and move along the AHL concentration gradient toward the pathogen. 3. Killing Module. The killing module in this design contains two pathogen killer molecules that are expressed and secreted from the "Seek and Kill" E. coli cells once AHL enters the engineered E. coli cells. The first killer molecule is DNase I that degrades the biofilm, creating access for the second killer molecule. The second killer molecule is Microcin-S, an antimicrobial peptide that targets and kills P. aeruginosa cells.
The experimental design included testing the efficacy of each module and of the entire in vitro system. film disruption, and cell killing. For PA cells in planktonic form (free cells), cell viability results showed 50% killing. For PA cells in biofilm communities, test results showed 60% reduction in biofilms and 40% cell killing.
Results

Discussion and Conclusions
The genetically engineered "Seek and Kill" E. coli in vitro system demonstrated effective cell killing of PA cells regardless of whether the PA cells were in planktonic "free cell" form or in biofilm communities.
Topic Discussion
Are Genetically-Engineered Probiotics Necessary? Can Non-Recombinant Probiotics Be Used Effectively Instead?
Non-recombinant probiotics have been used successfully in prevention and treatment of some infectious diseases (Lambert, 2011) , particularly ones affecting the GI tract (e.g., Clostridium difficile; Pattani et al., 2013) and some bacterial diseases affecting skin (e.g., MRSA; Sikorska & Smoragiewicz, 2013) . Probiotics have also demonstrated some efficacy in alleviating clinical symptoms of some viral infections (e.g., influenza; Waki et al., 2014) . Probiotics along with prebiotics (Quigley, 2010) have been used successfully as sole treatments and as adjuncts to standard antibiotic treatments and are thought to work as antibiotics mainly through probiotics competing with pathogenic bacteria as well as by boosting the host's immune system via probiotic interactions with the gut-associated immune system (Oelschlaeger, 2010) .
Thus, the question arises whether it is necessary to engineer bacteria such as "Seek and Kill" E. coli that target specific pathogens in lieu of simple treatments (preventative and therapeutic) with non-recombinant probiotics. The evidence points to effective use of non-recombinant probiotics in some cases and continued experimentation in this area appears worthwhile. Given the looming antibiotic resistance crisis, however, the wisest course is likely to be exploring multiple approaches simultaneously.
Potential Next Steps
System Modifications. The in vitro system could potentially be improved by modifications to boost motility (e.g., optimizing chemotactic parameters to increase motility distance), biofilm degradation (e.g., optimizing condi-
Figure 1
Directed chemotaxis-guided motility of E. coli upon induction by AHL-reprogrammed "Seek and Kill" system in E. coli.
The system is divided into three genetic devices: Under LasR-AHL (N-Acyl homoserine lactone) responsive promoter, pLasI, expression of CheZ (Motility) and secretion tagged proteins (Killing) are induced by the quorom sensing molecule (Sensing). In the presence of a quorom sensing molecule (AHL) from P. aeruginosa, reprogrammed E. coli cells express CheZ to swim toward the pathogen. Further gene expression is initiated in E. coli to secrete antibiofilm (DNaseI) and antimicrobial peptide (MccS) to degrade biofilm and kill planktonic or biofilm-residing cells that are released by the biofilm degradation. pJ23108: constitutive promoter. YebF: secretion tag. mccS: gene encoding for microcin S (MccS).
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tions for DNase I activity or using additional degradatative enzymes), and cell killing (e.g., optimizing conditions for Microcin-S or increasing types of cell killing molecules). Expanding the Approach to Target and Kill Other Pathogens. Since in vivo biofilm communities are not likely to consist solely of PA cells and the activities of DNase I and Microcin-S are not limited to PA, the potential exists that this system could be used against a broad range of pathogens. In addition, other biofilm degradation and cell killing molecules including other antimicrobial peptides could be incorporated into the system to enable killing of pathogens for which DNase I and Microcin-S do not display adequate killing potential.
Expanding the Approach to In Vivo Killing of Pathogens. To be an effective alternative to antibiotics, animal studies and eventually human clinical trials will need to be done that demonstrate both efficacy and safety.
Potential Limitations
Technological limitations may prevent expansion of this approach to other pathogens and/or expansion of the approach to whole organisms, including humans. The authors did not discuss any of the potential hurdles that would need to be overcome for the approach to be successfully applied in vivo in animal models or in humans. The system would be counted a success, however, even if it only worked against PA cells in animals and humans.
Off-target effects would likely be a major concern. Conceivably, the "Seek and Kill" E. coli could be erroneously targeted against the host's normal microbiota, possibly involving mutation(s) and/or exchange of genes between the pathogen and probiotic-type bacteria in the host's gastrointestinal (GI) tract. Such off-target effects on probiotic bacteria that indirectly affect the host seem unlikely since the system has been developed to specifically target pathogenic bacteria, but this possibility cannot be ruled out until in vivo experiments are performed.
The possibility of off-target effects that may create serious side-effects in the host directly is also of concern. There could be deleterious effects on the host (e.g., through expression of killing molecules) that are unforeseen at this point. This possibility also needs to be tested in animal studies, and should those concerns be ruled out successfully in animals, similar tests would need to be done in human clinical trials.
Institutional Biosafety Committee Considerations
It is expected that biosafety level 1 (BSL-1) would be determined appropriate by most Institutional Biosafety Committees (IBCs) for most aspects of "Seek and Kill" E. coli research since experiments with nonpathogenic E. coli are generally done at BSL-1 conditions. Once a system was developed to target a specific pathogen, however, the IBC would consider the target pathogen's risk group and other potential risks of materials and procedures to decide the appropriate biosafety level for efficacy tests of the "Seek and Kill" E. coli. In general, BSL-2 would be expected for risk group 2 pathogens, BSL-3 for risk group 3 pathogens, etc. The IBC would, of course, need to consider any unforeseen hazards associated with the "Seek and Kill" E. coli system, including any off-target effects, when determining appropriate safety levels and precautions for these experiments.
Conclusions
We do not yet know whether the "Seek and Kill" E. coli system will demonstrate effective and safe pathogen cell killing in in vivo situations, for other pathogens, or as a broad spectrum antimicrobial, but the well-designed Hwang et al. study provides enough positive results to make their approach a promising avenue to pursue.
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